靶向抗癌药推广应用的瓶颈及思考

Bottlenecks and Thinking on the Popularization and Application of the Targeted Cancer Drugs

我国癌症高发凸显,但肿瘤医学也进入了个性化治疗、精确治疗的崭新时代,靶向抗癌药逐步应用于临床。对癌症靶向治疗的疗效评价不同于传统治疗,除了治疗观念的改变,抗肿瘤药物评价标准也发生改变,靶向药物评价的风险比亦得到普遍认同,风险比越小,患者获益越大。但分子靶向抗癌药高昂的价格仍成为其临床运用的最大瓶颈。为此,应明确靶向抗癌药的可及性,加快部分药物纳入医保目录,探索慈善捐赠与医保结合的推广方式,并合理降价,提高性价比。

A high incidence of cancer has occurred in our country, but cancer medicine has also entered the new era of personalized treatment and accurate treatment. Targeted cancer drugs are gradually applied in clinical treatment. The evaluation of curative effect for targeted cancer therapy is different from that of traditional treatment. Besides the change of treatment concept,the standard to evaluate the effect of antitumor drugs is also changed. Hazard ratio has been widely accepted as a criterion to evaluate the risk of targeted g drugs. The smaller the hazard ratio, the greater the benefit obtained by the patients. However, the high price of molecular targeted cancer drugs demonstrated to be the biggest challenge for its clinical use. Therefore, the accessibility of targeted cancer drugs should be well understood and some of the target drugs should be put in the medical insurance directory quickly. The way of combining the charity donations with health care insurance should be explored, the price of the target drugs should be reduced to a reasonable range and the cost performance ratio should be improved.